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protracted oromucositis in BMT recipients [7, 9] that is of quite
a different character than the milder form induced by cytara-
bine. In contrast, high doses of cytarabine can be profoundly
toxic to the gut and lungs [10]. The colonization of the stomach
or digestive tract might therefore provide the alternative portal
of entry that Bochud and colleagues suggested. Extensive colon-
ization of the stomach and the small intestine would also be
facilitated by any H2 antagonists used to manage the dyspepsia
that frequently occurs following cytostatic chemotherapy.
The use of these agents was also implicated by Elting and
associates [5] as a significant risk factor for the development of
the so-called alpha strep shock syndrome. Moreover, patients
with oromucositis tend to swallow large volumes of slimy
mucus, which may assist in protecting the oral streptococci.
Therefore, the presence of gastrointestinal colonization in pa-
tients with bacteremia due to S. mitis might explain why only a
minority of these patients go on to develop the alpha strep shock
syndrome; the microbial load may well be sufficient to elicit the
release of cytokines that are necessary to induce sepsis syn-
drome, adult respiratory distress syndrome, and, in some cases,
fatal multiorgan failure.
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Reply
SIR—We agree with Donnelly et al. that bacteremia due to oral
viridans streptococci (OVS) in neutropenic patients with cancer
has occurred not only while the patients were receiving prophy-
laxis with fluoroquinolones but also while they were receiving
other prophylactic antibiotic regimens. This finding was inad-
vertently omitted in our text but cited in the references. The
interesting data of Donnelly et al. as well as data from other
centers, including ours, clearly suggest that aggressive cytostatic
chemotherapy is probably the key factor predisposing neutro-
penic patients to OVS bacteremia. However, it appears clear
that several widely used prophylactic agents, including fluoro-
quinolones and co-trimoxazole, are not effective in preventing
OVS bacteremia. Moreover, OVS bacteremia was practically un-
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known before the use of these prophylactic regimens, and two
case-control studies have shown an association between the use
of quinolones or co-trimoxazole and the occurrence of OVS bac-
teremia [ 1, 2]. Thus, certain prophylactic antibiotics may not
only be ineffective in preventing OVS bacteremia, but they may
also alter the endogenous bacterial flora in a way that predis-
poses susceptible patients to the infection.
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